99 completed, 24 terminated, 18 recruiting, 17 active not recruiting. 90 Phase 2, 52 Phase 3, 37 Phase 1, 8 Phase 4, 7 Not applicable.
Follow bicalutamide: new trials by email Literature Review of bicalutamide trials Research Report on bicalutamide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Prostate Specific Membrane Antigen (PSMA) Imaging for Detection of Residual and Metastatic Prostate Cancer Bicalutamide, Prostate-specific membrane antigen Positron Emission Tomography-Computed Tomography, 18F-rhPSMA-7.3 - Prostate Cancer, Recurrent Prostate Cancer | Phase 2 | Not yet recruiting | Washington University School of Medicine | 20 | 2026-10-31 | 2026-09-11 |
| A Study to Learn How Enzalutamide, Apalutamide and Bicalutamide Affect the Way Fezolinetant is Processed in Men With Prostate Cancer fezolinetant, enzalutamide, apalutamide - Prostate Cancer | Phase 1 | Recruiting | Astellas Pharma Global Development, Inc. | 56 | 2026-09-25 | 2026-10-16 |
| Autonomic and Renal Contributions to Hypertension With ADT Gonadotropin Releasing Hormone Agonists (GNRH), Androgen receptor (AR) inhibitor, Placebo - Androgen Deprivation Therapy, Prostate Cancer | Phase 4 | Recruiting | Virginia Commonwealth University | 50 | 2026-08-01 | 2026-09-30 |
| Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT Leuprolide, Degarelix, Relugolix - Prostate Cancer, Localized Prostate Carcinoma | Phase 2 | Recruiting | Baptist Health South Florida | 50 | 2026-07-29 | 2026-08-06 |
| A Randomized Trial of Bicalutamide in Non-Muscle Invasive Bladder Cancer Bicalutamide, Biopsy Procedure, Biospecimen Collection - Non-Muscle Invasive Bladder Urothelial Carcinoma, Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma | Phase 1 | Recruiting | University of Wisconsin, Madison | 80 | 2026-06-25 | 2026-09-30 |
| Androgen-responsive POSLUMA-guided Intra-prostatic Boost PSMA PET/CT, Androgen Deprivation Therapy (ADT) +/- bicalutamide, Stereotactic Body Radiation Therapy (SBRT) +/- focal microboost - Intermediate Risk Prostate Cancer, High Risk Prostate Cancer | Phase 2 | Recruiting | Martin T. King, MD, PhD | 23 | 2026-04-29 | 2026-05-29 |
| A Study of Disitamab Vedotin + Bicalutamide in HER2/AR-Positive Scrotal Paget's Disease Disitamab Vedotin combined with Bicalutamide - Extramammary Paget Disease, Scrotum Disease | Phase 2 | Recruiting | Fudan University | 20 | 2025-08-01 | 2025-08-12 |
| Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer Gonadotropin Releasing Hormone Agonists and Antagonists, Bicalutamide, Biopsy Procedure - High Risk Prostate Carcinoma, Localized Prostate Adenocarcinoma | Phase 2 | Withdrawn | OHSU Knight Cancer Institute | 2025-04-16 | 2025-09-23 | |
| A Study of Bicalutamide With Brain Re-irradiation to Treat Recurrent/Progressive High Grade Glioma Bicalutamide, Intensity-modulated radiation therapy (IMRT) - Recurrent Glioblastoma, Recurrent High-grade Glioma | Phase 1 | Withdrawn | University of Nebraska | 2025-04-08 | 2025-07-22 | |
| REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial Abiraterone Acetate, Bicalutamide, Biospecimen Collection - Recurrent Prostate Carcinoma, Stage III Prostate Cancer AJCC v8 | Phase 3 | Recruiting | Emory University | 72 | 2025-01-31 | 2026-02-24 |
| Study to Evaluate the Safety and Efficacy of Bicalutamide in Combination With Sunitinib in Patients With TKIs-resistant RCC Bicalutamide in combination with Sunitinib - Carcinoma, Renal Cell | Phase 1 / Phase 2 | Recruiting | State University of New York at Buffalo | 28 | 2024-10-01 | 2026-04-01 |
| Bicalutamide and Abemaciclib in Inoperable or Metastatic Androgen Receptor-positive Triple-negative Breast Cancer Abemaciclib, Bicalutamide - Triple Negative Breast Neoplasms | Phase 2 | Recruiting | Universitaire Ziekenhuizen KU Leuven | 53 | 2024-04-08 | 2026-04-01 |
| Bicalutamide Therapy in Young Women With NAFLD and PCOS Bicalutamide 50 mg, Placebo - NAFLD, PCOS | Phase 1 | Recruiting | University of California, San Francisco | 50 | 2024-02-14 | 2026-05-29 |
| A Canadian Trial of Bicalutamide in Patients Receiving Maintenance Avelumab for Metastatic Urothelial Cancer. Bicalutamide 150 mg, Placebo - Metastatic Urothelial Carcinoma | Phase 2 | Withdrawn | CHU de Quebec-Universite Laval | 2023-11-07 | 2024-02-15 | |
| Contributions to Hypertension With Androgen Deprivation Therapy Gonadotropin Releasing Hormone Agonists (GNRH), Androgen receptor (AR) inhibitor, Placebo - Androgen Deprivation Therapy, Prostate Cancer | Phase 4 | Terminated | University of Colorado, Denver | 10 | 2023-09-20 | 2026-09-02 |
| Pharmacogenomics IND Commercial SNP Clinical Study - Abiraterone and Single Nucleotide Polymorphisms Abiraterone - Usual, Abiraterone - Study - Prostate Cancer | Phase 2 / Phase 3 | Active not recruiting | Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair | 600 | 2023-08-18 | 2026-06-10 |
| Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing Cohort 1 (HER2-positive, RC48-ADC), Cohort 2 (NTRK-fusion or NTRK-mutant), Cohort 3 (AR-positive, leuprolide + bicalutamide + abiraterone) - Salivary Gland Carcinoma, Precision Therapy | Phase 2 | Recruiting | Peking Union Medical College | 39 | 2023-08-15 | 2026-04-02 |
| The RolE oF Androgen Excess in MUscle Energy MetaboLism in Women With PolyCystic Ovary Syndrome (REFUEL PCOS) Study 2 Bicalutamide 50 mg - Polycystic Ovary Syndrome, Androgen Excess | Not applicable | Unknown | Royal College of Surgeons, Ireland | 16 | 2023-01-01 | 2022-12-12 |
| Phase II Dutasteride in Combination With CAB vs CAB in SDC Goserelin 10.8 mg, Bicalutamide 50 mg, Dutasteride 0.5 mg - Salivary Duct Carcinoma | Phase 2 | Recruiting | Radboud University Medical Center | 26 | 2022-09-27 | 2025-06-04 |
| A Phase II Trial of Bicalutamide in Patients Receiving Intravesical BCG for Non-muscle Invasive Bladder Cancer Bicalutamide, Control Arm - Non-Muscle Invasive Bladder Cancer | Phase 2 | Recruiting | CHU de Quebec-Universite Laval | 160 | 2022-06-23 | 2025-12-18 |
Showing 20 of 188. Sign in to see all of them.
Prostatic Neoplasms (143) · Breast Neoplasms (10) · Neoplasm Metastasis (8) · Bulbo-Spinal Atrophy, X-Linked (5) · Neoplasms (5) · Triple Negative Breast Neoplasms (4) · COVID-19 (3) · Salivary Gland Neoplasms (3) · Coronavirus Infections (2) · Hirsutism (2) · Hypertension (2) · Kidney Diseases (2) · Lower Urinary Tract Symptoms (2) · Osteoporosis (2) · Primary Dysautonomias (2)
AstraZeneca (14) · Radiation Therapy Oncology Group (9) · National Cancer Institute (NCI) (8) · Dana-Farber Cancer Institute (5) · European Organisation for Research and Treatment of Cancer - EORTC (5) · M.D. Anderson Cancer Center (5) · Memorial Sloan Kettering Cancer Center (5) · SWOG Cancer Research Network (5) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (5) · Mayo Clinic (4) · CHU de Quebec-Universite Laval (3) · Ferring Pharmaceuticals (3) · Fudan University (3) · NCIC Clinical Trials Group (3) · NRG Oncology (3)
United States (112) · Canada (36) · China (13) · France (12) · United Kingdom (11) · Belgium (10) · Germany (8) · Italy (8) · Netherlands (8) · Spain (6) · Czechia (5) · Poland (5) · Ireland (4) · Israel (4) · Mexico (4)
Mary-Ellen Taplin, MD (4) · Kenneth Pienta, MD (3) · Richard Larouche, M.D. (3) · Catherine H Marshall, MD/MPH (2) · Christopher Logothetis (2) · Giovanni Luca Gravina, M.D. (2) · Jacqueline Vuky, MD (2) · Matthew Babcock, PhD (2) · Michel Bolla, MD (2) · Nigel J Parr, MBBS, FRCS(Urol), MD (2) · Robert DiPaola (2) · Abdenour Nabid, MD (1) · Abhishek Solanki, MD MS (1) · Ajjai Alva, M.D. (1)
PMID 34350976, PMID 22129214, PMID 23533230, PMID 30189902, PMID 38421243, PMID 16921051, PMID 17918264, PMID 18309951, PMID 18349405, PMID 18990504, PMID 19029421, PMID 19516032, PMID 19682889, PMID 20818327, PMID 20950306, PMID 21502546, PMID 22056152, PMID 22119204, PMID 22500884, PMID 22928480, PMID 22931259, PMID 23257248, PMID 23258223, PMID 23550669, PMID 23851165, PMID 24323034, PMID 24993934, PMID 25087673, PMID 25534388, PMID 25691677, PMID 25732157, PMID 25847934, PMID 26014295, PMID 26028518, PMID 26209502, PMID 26681677, PMID 26720308, PMID 26774508, PMID 26811535, PMID 26976418, PMID 27459586, PMID 27497762, PMID 27756786, PMID 28146658, PMID 28433432, PMID 28581398, PMID 29624463, PMID 30245169, PMID 31434793, PMID 32067679
2008 (3), P30CA015083 (3), U10CA032102 (3), U10CA180868 (3), P30CA008748 (2), P30CA016672 (2), P30CA033572 (2), U10CA021115 (2), 2015 (1), 2023 (1), I01CX002277 (1), K01HL164978 (1), N01CM00032 (1), N01CM62201 (1), N01CM62203 (1)